Introduction COVID-19 infection can trigger irritable bowel syndrome (IBS) in previously asymptomatic individuals, with research indicating that the risk of developing IBS after COVID is approximately 9%
11 In April 2026 the FDA removed BPC-157 (along with several other peptides) from that interim list, but it is important to read that move correctly: it was a procedural step tied to withdrawn nominations and a fresh review under the Section 503A framework, not a finding that the compound is safe or effective, and it did not add BPC-157 to the positive list of substances sanctioned for compounding
Recent case study results show quick symptom improvement, with itching and scaling stopping shortly after starting liraglutide treatment, which points to anti-inflammatory qualities separate from weight loss benefits
Heterosynaptic Plasticity of Excitatory Inputs to Inhibitory Neurons Nonsynaptic mechanisms can produce [Ca 2+ ] i rise to the thresholds necessary to induce long-term plasticity not only at activated synapses, but also at nonactivated synapses, leading to heterosynaptic plasticity
Additionally, we did not grade comorbid conditions at baseline, which might have caused some selection bias in the cohorts
